Skip to main content

Table 1 Baseline characteristics of the 2,656 participants of HYVET for whom the frailty index was calculable, by treatment group

From: No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over

  Placebo Active
n 1,324 1,332
Age (yrs), mean (SD) 83.4 (3.0) 83.6 (3.2)
Male 520 (39.3%) 526 (39.5%)
Female 804 (60.7%) 806 (60.5%)
Body mass index*   
Underweight 39 (3%) 58 (4%)
Normal weight 587 (44%) 605 (46%)
Overweight 566 (43%) 530 (40%)
Obese 132 (10%) 138 (10%)
Sitting SBP, mean (SD) 173.1 (8.9) 173.3 (8.8)
Sitting DBP, mean (SD) 90.0 (8.9) 89.9 (8.8)
Standing SBP, mean (SD) 168.0 (11.8) 168.2 (11.9)
Standing DBP, mean (SD) 87.9 (9.9) 88.1 (9.8)
Cardiovascular disease, n (%) 177 (13.4%) 159 (11.9%)
Antihypertensive treatment prior to entry into the trial, n (%) 830 (62.7%) 828 (62.2%)
Mini Mental State Examination, median (IQR) 26.0 (22–28) 26.0 (22–28)
Frailty Index, median (IQR) 0.17 (0.11–0.24) 0.16 (0.11–0.24)
  1. *Adjusted for region of recruitment.
  2. DBP, Diastolic blood pressure; IQR, Interquartile range; SBP, Systolic blood pressure; SD, Standard deviation.